Publikationen in Zusammenarbeit mit Forschern von Cancer Research UK (4)

2020

  1. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial

    Journal of Clinical Oncology

2019

  1. POSEIDON trial phase 1B results: Safety, efficacy and circulating tumor DNA response of the beta isoform-sparing PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor positive metastatic breast cancer patients

    Clinical Cancer Research, Vol. 25, Núm. 22, pp. 6598-6605

  2. The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer

    Cell Reports, Vol. 27, Núm. 9, pp. 2690-2708.e10

2018

  1. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    EMBO Molecular Medicine, Vol. 10, Núm. 12